UK Telemedicine Solutions Provider Selects GEMS(TM) ECG Technologies for Expanded Service Offerings
Toronto, Ontario--(Newsfile Corp. - October 2, 2017) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm Solutions" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") management software solutions, today announced that it has completed a custom software engineering contract with UK based Remote Diagnostic Technologies Limited ("RDT") for development and licensing of a remote, cloud-based, 12 lead ECG management and ECG reading solution. RDT specializes in the design of highly integrated mobile, vital signs, tele-monitoring solutions used globally.
The engagement of CardioComm Solutions followed an international search for a credible solutions provider that could meet RDT's exacting performance, scalability and stability requirements. In addition to their technical capabilities, a pivotal factor in selecting CardioComm Solutions was the Company's capability to ensure completion of the project to meet RDT customer's growing use needs. RDT counts a wide range of global customers in prehospital care markets covering military, ambulance, civilian, aviation, shipping and mining and exploration applications. Of significance is the project utilizes a customized adaptation of the Company's newest ECG management and viewing technology platform named GEMS™ Flex which is scheduled for commercial release in 2018.
The new RDT platform with the integrated ECG management solution will:
support use of RDT's existing portable Tempus Pro devices;
provide simultaneous exchange of patient data from multiple devices through the RDT Gateway Service;
involve the development and use of a custom ECG Engine to convert 12-Lead ECG files generated by the RDT vital signs monitors into compatible formats for report generation purposes;
share wirelessly transmitted patient data with, and provide administration functionality over, a proprietary RDT Application Server where encounter data is centrally managed and medical reviews performed; and,
deliver a novel 12 Lead ECG viewer to enable HTML5 compatible, browser-based viewing and interactive reviewing of 12 Lead ECGs displayed on computers and mobile devices.
CardioComm Solutions has a rich history of providing companies with innovative and scalable ECG connectivity technology solutions. Larger engineering engagements announced previously include customized telemedicine and mobile cardiac monitoring software development and multi-year agreements with associated recurrent licensing and royalty revenue streams.
About Remote Diagnostic Technologies
Founded in 1997 RDT is recognized as leaders in the design and manufacture of pre-hospital care vital signs monitors. Specialist technologies include compact and highly integrated vital signs monitors for medical professional, intermittent and non-medically trained users that are widely used in aviation, maritime, exploration and military environments. RDT's communications technology enables the simultaneous transmission of medical data, voice and video from these remote and otherwise isolated locations — including in-flight and at sea — to land-based medical experts. RDT's impressive international customer base includes leading airlines (Virgin Atlantic, Etihad, Emirates, V Australia), Fortune 500 companies, commercial shipping, luxury yachts and the military.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada.
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact email@example.com